A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)

Inclusion Criteria:

• Be willing and able to understand the study procedures and the risks involved andprovide written informed consent before the first study-related activity

• DME patients must be ≥ 18 years of age, NVAMD patients must be ≥ 50 years of age

• Diagnosis of either DME or NVAMD. DME patients must be treatment naïve. NVAMDpatients can be either treatment naïve or treatment experienced.

• DME patients must have vision loss in the study eye

• NVAMD patients can be either treatment-naïve or treatment experienced with visionloss in the study eye

Exclusion Criteria:

• Be pregnant or breastfeeding

• History of cataract surgery and/or minimally invasive glaucoma surgery (MIGS) within 3 months of Screening

• Yttrium-Aluminum Garnet (YAG) laser capsulotomy within 2 months of Screening

• Any other condition except for DME or NVAMD or that could affect interpretation ofstudy assessments